Shares of Givaudan SA (OTCMKTS:GVDNY – Get Free Report) have received an average recommendation of “Hold” from the eight analysts that are presently covering the firm, Marketbeat.com reports. Five investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company.
GVDNY has been the subject of a number of analyst reports. Kepler Capital Markets lowered Givaudan from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 13th. Barclays lowered Givaudan from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 27th. Berenberg Bank downgraded Givaudan from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Zacks Research raised Givaudan from a “strong sell” rating to a “hold” rating in a research note on Monday, May 18th. Finally, Deutsche Bank Aktiengesellschaft raised Givaudan from a “hold” rating to a “buy” rating in a research note on Tuesday, June 9th.
Read Our Latest Stock Analysis on Givaudan
Givaudan Stock Performance
Givaudan Company Profile
Givaudan is a Swiss-based global company that develops, manufactures and supplies flavors, fragrances and active cosmetic ingredients for a broad range of consumer products. The company’s core activities are organized around creating taste and scent solutions—ranging from fine fragrances and consumer-packaged goods scents to flavor systems for food and beverages and functional ingredients for personal care. Givaudan works with brand owners and manufacturers to design sensory experiences, improve product performance and meet formulation or regulatory requirements.
Its product and service offerings include bespoke fragrance creation, flavor formulation, natural ingredient sourcing, aroma chemicals, taste modulators and application support such as prototyping and sensory testing.
Recommended Stories
- Five stocks we like better than Givaudan
- 3 Retail Winners Using Cash Flow to Stay Ahead
- 3 Tech ETFs That Could Bounce Back After the AI Selloff
- 3 Penny Stocks Under $5 Backed by Real Revenue Growth
- 3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend
Receive News & Ratings for Givaudan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Givaudan and related companies with MarketBeat.com's FREE daily email newsletter.
